Switching Undetectables to Selzentry

Summary

This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] and switch them to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs.

Timeline

Start

2013-01

Primary completion

2013-12

Completion

2014-06

Drugs

Indications